Lesley Burgess - Researcher Profile | RDL Research Database

Publications

2 shown

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal , Evan A. Stein , Robert Dufour +15 more

2014 The Lancet 730 citations

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom , Tomas Hala , Michael A. Bolognese +13 more

At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in pat...

2014 New England Journal of Medicine 697 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 1,427
Institution: Tygerberg Hospital

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-4457-0596

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.